

# Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/D43322ACD785EN.html>

Date: May 2022

Pages: 76

Price: US\$ 2,000.00 (Single User License)

ID: D43322ACD785EN

## Abstracts

Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Drugs In Development, 2022, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 4, 4, 8, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).

The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

- Introduction
- Global Markets Direct Report Coverage
- Drug Overdose - Overview
- Drug Overdose - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Drug Overdose - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Overdose - Companies Involved in Therapeutics Development
- Amphastar Pharmaceuticals Inc
- Avior Bio Inc
- Clear Scientific LLC
- Crossject SA
- Egetis Therapeutics AB
- Emergent BioSolutions Inc
- Enalare Therapeutics Inc
- Fab'entech SA
- Hepione Therapeutics Inc
- Icure Pharmaceutical Inc
- InterveXion Therapeutics LLC
- Klaria Pharma Holding AB
- Mucodel Pharma LLC
- Nasus Pharma Ltd
- Opiant Pharmaceuticals Inc
- Orexo AB
- ResQ Pharma Inc
- Sparian Biosciences Inc
- Vallon Pharmaceuticals Inc
- Vernalis R&D Ltd
- Worphmed Srl
- Drug Overdose - Drug Profiles

Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile

Product Description

Mechanism Of Action

drinabant - Drug Profile

Product Description

Mechanism Of Action

History of Events

ENA-001 - Drug Profile

Product Description

Mechanism Of Action

IXTf-250 - Drug Profile

Product Description

Mechanism Of Action

IXTM-200 - Drug Profile

Product Description

Mechanism Of Action

History of Events

melatonin - Drug Profile

Product Description

Mechanism Of Action

History of Events

nalmefene - Drug Profile

Product Description

Mechanism Of Action

History of Events

nalmefene - Drug Profile

Product Description

Mechanism Of Action

History of Events

nalmefene - Drug Profile

Product Description

Mechanism Of Action

naloxone - Drug Profile

Product Description

Mechanism Of Action

History of Events

naloxone - Drug Profile

Product Description

Mechanism Of Action

History of Events  
naloxone - Drug Profile  
Product Description  
Mechanism Of Action  
naloxone - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naloxone - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naloxone hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naloxone hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naloxone hydrochloride 1 - Drug Profile  
Product Description  
Mechanism Of Action  
naloxone. - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
OPNT-006 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
physostigmine - Drug Profile  
Product Description  
Mechanism Of Action  
PP-100 - Drug Profile  
Product Description  
Mechanism Of Action  
SBS-371 - Drug Profile  
Product Description

Mechanism Of Action

Small Molecule for Acute Opioid Overdosage - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Substance Abuse and Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

V-24343 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vaccine for Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

Vaccine for Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

Drug Overdose - Dormant Projects

Drug Overdose - Discontinued Products

Drug Overdose - Product Development Milestones

Featured News & Press Releases

Apr 01, 2022: Anebulo Pharmaceuticals doses more than half of the subjects in part A of a phase 2 clinical trial and provides guidance on IND submission

Feb 08, 2022: Teva agrees to pay \$225m to settle opioid claims in Texas

Jan 03, 2022: Anebulo Pharmaceuticals announces initiation of phase 2 clinical study evaluating ANEB-001 for the treatment of acute cannabinoid intoxication

Dec 20, 2021: Klaria Pharma initiates clinical study with Naloxon Alginate Film

Dec 02, 2021: Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film

Nov 16, 2021: Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124

Oct 22, 2021: Klaria Pharma announces approval by the United States Patent and



Trademark Office of a new patent application covering naloxone alginate film

Oct 13, 2021: Anebulo Pharmaceuticals announces issuance of U.S. patent covering use of ANEB-001 for the treatment of acute Cannabinoid overdose

Sep 13, 2021: Anebulo Pharmaceuticals announces completion of manufacturing of ANEB-001 capsules for upcoming phase 2 clinical trial

Jul 16, 2021: Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial

Apr 13, 2021: Nasus Pharma announces positive results in pivotal trial of FMXIN001 Naloxone powder-based nasal spray for the treatment of opioid overdose

Feb 08, 2021: Opiant Pharmaceuticals announces first patient dosed in confirmatory pharmacokinetic study assessing OPNT003, nasal nalmefene, for the treatment of opioid overdose

Feb 05, 2021: Klaria announces patent approval in Europe of a new product patent covering Naloxone Alginate Film

Jan 29, 2021: Orexo expects FDA filing of OX124 mid 2022

Jan 27, 2021: Orexo strengthens IP rights for overdose rescue drug OX124

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Drug Overdose, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, 2022  
Drug Overdose - Pipeline by Avior Bio Inc, 2022  
Drug Overdose - Pipeline by Clear Scientific LLC, 2022  
Drug Overdose - Pipeline by Crossject SA, 2022  
Drug Overdose - Pipeline by Egetis Therapeutics AB, 2022  
Drug Overdose - Pipeline by Emergent BioSolutions Inc, 2022  
Drug Overdose - Pipeline by Enalare Therapeutics Inc, 2022  
Drug Overdose - Pipeline by Fab'entech SA, 2022  
Drug Overdose - Pipeline by Hepione Therapeutics Inc, 2022  
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, 2022  
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, 2022  
Drug Overdose - Pipeline by Klaria Pharma Holding AB, 2022  
Drug Overdose - Pipeline by Mucodel Pharma LLC, 2022  
Drug Overdose - Pipeline by Nasus Pharma Ltd, 2022  
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, 2022  
Drug Overdose - Pipeline by Orexo AB, 2022  
Drug Overdose - Pipeline by ResQ Pharma Inc, 2022  
Drug Overdose - Pipeline by Sparian Biosciences Inc, 2022  
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, 2022  
Drug Overdose - Pipeline by Vernalis R&D Ltd, 2022  
Drug Overdose - Pipeline by Worphmed Srl, 2022  
Drug Overdose - Dormant Projects, 2022  
Drug Overdose - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Drug Overdose, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/D43322ACD785EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D43322ACD785EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

